Food and drug administration approved adjuvant cemiplimab (libtayo) for adults with cutaneous squamous cell carcinoma who are at a high risk for recurrence after surgery and radiation. The company also announced that the fda has extended approval for evkeeza to treat young children with homozygous familial hypercholesterolemia, a condition marked by high ldl cholesterol. Fda label information for this drug is available at dailymed Basal cell carcinoma (bcc) (a type of skin cancer). The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026.
In addition, the company has submitted an application to include an additional vial filler, with an fda decision regarding this new vial filler expected by late december 2025
WATCH
